The Biosimilars Forum Comments on FDA’s New Interchangeability Guidance for Industry
WASHINGTON, D.C. (May 10, 2019) – Following the FDA’s issuance of final interchangeability guidance today, the Biosimilars Forum today issued the following statement:
The Biosimilars Forum is encouraged by the FDA’s serious approach and support of biosimilars. The Forum believe this guidance is an improvement over the previous draft guidance and each of our respective companies are now closely analyzing its potential impact. We look forward to continue its work with the FDA on this update and other policies that support biosimilar use in the U.S.